Barry Bunin, PhD, Founder & CEO, Collaborative Drug Discovery

Barry Bunin, Ph.D. CEO & Board Director Collaborative Drug Discovery & CDD Vault

Barry A. Bunin, Ph.D. is the CEO of Collaborative Drug Discovery. Dr. Bunin has overseen $50 million+ in business transactions over the last two decades. Prior to CDD, he was an Entrepreneur in Residence with Eli Lilly & Co. Dr. Bunin is on a patent for Kyprolis™ (Carfilzomib for Injection) — a selective proteasome inhibitor that received accelerated FDA approval for the treatment of patients with multiple myeloma that was widely viewed as the centerpiece of Amgen’s $10.4 Billion acquisition of Onyx Pharmaceuticals.

Dr. Bunin was the founding CEO, President, & CSO of Libraria (now Eidogen-Sertanty). At Libraria, he led a team that integrated exhaustive reaction capture (synthetic chemistry) with gene-family wide SAR capture (medicinal chemistry). On the scientific side, he co-authored “Chemoinformatics: Theory, Practice, and Products” (Springer-Verlag), a text that overviews modern chemoinformatics technologies, and “The Combinatorial Index” (Academic Press), a widely used text on high-throughput chemical synthesis.

In the lab, Dr. Bunin did medicinal synthetic chemistry developing patented new chemotypes for protease inhibition at Axys Pharmaceuticals (now Celera) and RGD mimics to inhibit GP-IIbIIIa at Genentech. Dr. Bunin received his B.A. from Columbia University and his Ph.D. from UC Berkeley, where he synthesized and tested the initial 1,4-benzodiazepine libraries with Professor Jonathan Ellman.

Education

Columbia University
BA, Chemistry (Advisor N. J. Turro)
Physical Organic Chemistry and Education

UC Berkeley
Ph.D., Bioorganic Chemistry (Advisor Jonathan Ellman)
Bioorganic synthetic chemistry

Patents

  • Hybrid machine-user learning system and process for identifying, accurately selecting and storing scientific data. (U.S. Patent No. 9,594,743, issued March 14, 2017)
  • Compounds for enzyme inhibition (US Patent 8,324,174, Issued, Dec 4, 2012)
    • Patent(s) for Kyprolis™ (Carfilzomib for Injection) — a selective proteasome inhibitor that received accelerated FDA approval for the treatment of patients with multiple myeloma that was widely viewed as a centerpiece of Amgen’s $10.4 Billion acquisition of Onyx Pharmaceuticals.
  • Method of flexibly generating diverse reaction chemistries. (US Patent WO 2003044219, Filed Nov 19, 2002)
    • Computational tools automatically suggest/generate diverse reaction sets for particular precursors, classes of precursors, or different reaction chemistries. This is accomplished by automatically generating a group of reaction chemistries for a particular precursor or class of precursors. Some of the reactions and/or products may be produced without reliance on reactions and products reported in available references.

Patents

  • Hybrid machine-user learning system and process for identifying, accurately selecting and storing scientific data. (U.S. Patent No. 9,594,743, issued March 14, 2017)
  • Compounds for enzyme inhibition (US Patent 8,324,174, Issued, Dec 4, 2012)
    • Patent(s) for Kyprolis™ (Carfilzomib for Injection) — a selective proteasome inhibitor that received accelerated FDA approval for the treatment of patients with multiple myeloma that was widely viewed as a centerpiece of Amgen’s $10.4 Billion acquisition of Onyx Pharmaceuticals.
  • Method of flexibly generating diverse reaction chemistries. (US Patent WO 2003044219, Filed Nov 19, 2002)
    • Computational tools automatically suggest/generate diverse reaction sets for particular precursors, classes of precursors, or different reaction chemistries. This is accomplished by automatically generating a group of reaction chemistries for a particular precursor or class of precursors. Some of the reactions and/or products may be produced without reliance on reactions and products reported in available references.

Citations

Citations 3217 762
h-index 26 15
i10-index 41 28

Publications

PUBLICATION TITLE CITED BY PUB YEAR
A general and expedient method for the solid-phase synthesis of 1, 4-benzodiazepine derivatives

BA Bunin, JA Ellman
Journal of the American Chemical Society 114 (27), 10997-10998
705 1992
The combinatorial synthesis and chemical and biological evaluation of a 1, 4-benzodiazepine library

BA Bunin, MJ Plunkett, JA Ellman
Proceedings of the National Academy of Sciences 91 (11), 4708-4712
455 1994
The combinatorial index

BA Bunin
Elsevier
376 1998
Novel web-based tools combining chemistry informatics, biology and social networks for drug discovery

M Hohman, K Gregory, K Chibale, PJ Smith, S Ekins, B Bunin
Drug discovery today 14 (5-6), 261-270
145 2009
Using open source computational tools for predicting human metabolic stability and additional absorption, distribution, metabolism, excretion, and toxicity properties

RR Gupta, EM Gifford, T Liston, CL Waller, M Hohman, BA Bunin, S Ekins
Drug Metabolism and Disposition 38 (11), 2083-2090
89 2010
Bayesian models leveraging bioactivity and cytotoxicity information for drug discovery

S Ekins, RC Reynolds, H Kim, MS Koo, M Ekonomidis, M Talaue, ...
Chemistry & biology 20 (3), 370-378
88 2013
A collaborative database and computational models for tuberculosis drug discovery

S Ekins, J Bradford, K Dole, A Spektor, K Gregory, D Blondeau, ...
Molecular BioSystems 6 (5), 840-851
86 2010
Chemoinformatics Theory

BA Bunin, B Siesel, GA Morales, J Bajorath
Chemoinformatics: Theory, Practice, & Products, 1-49
84 2007
Compounds for enzyme inhibition

MS Smyth, GJ Laidig, RT Borchardt, BA Bunin, CM Crews, JH Musser
US Patent 7,232,818
78 2007
Analysis and hit filtering of a very large library of compounds screened against Mycobacterium tuberculosis

S Ekins, T Kaneko, CA Lipinski, J Bradford, K Dole, A Spektor, K Gregory, ...
Molecular bioSystems 6 (11), 2316-2324
74 2010
Machine Learning Models and Pathway Genome Data Base for Trypanosoma cruzi Drug Discovery

S Ekins, J Lage de Siqueira-Neto, LI McCall, M Sarker, M Yadav, ...
PLoS neglected tropical diseases 9 (6), e0003878
67 2015
Enhancing hit identification in Mycobacterium tuberculosis drug discovery using validated dual-event Bayesian models

S Ekins, RC Reynolds, SG Franzblau, B Wan, JS Freundlich, BA Bunin
PloS one 8 (5), e63240
57 2013
Non Nucleic Acid Inhibitors of Protein⊙ DNA Interactions Identified through Combinatorial Chemistry

SY Stevens, BA Bunin, MJ Plunkett, PC Swanson, JA Ellman, GD Glick
Journal of the American Chemical Society 118 (43), 10650-10651
57 1996
Application of combinatorial and parallel synthesis to medicinal chemistry

BA Bunin, JM Dener, DA Livingston
Annual reports in medicinal chemistry 34, 267-286
51 1999
Compounds for enzyme inhibition

MS Smyth, GJ Laidig, RT Borchardt, BA Bunin, CM Crews, JH Musser, ...
US Patent 8,088,741
49 2012
Compounds for enzyme inhibition

MS Smyth, GJ Laidig, RT Borchardt, BA Bunin, CM Crews, JH Musser
US Patent 7,491,704
44 2009
Combinatorial chemistry

JN Abelson, MI Simon, GA Morales, BA Bunin
Elsevier
44 1996
Ten simple rules for cultivating open science and collaborative R&D

H Masum, A Rao, BM Good, MH Todd, AM Edwards, L Chan, BA Bunin, ...
PLoS computational biology 9 (9), e1003244
43 2013
Bayesian models for screening and TB Mobile for target inference with Mycobacterium tuberculosis

S Ekins, AC Casey, D Roberts, T Parish, BA Bunin
Tuberculosis 94 (2), 162-169
39 2014
Compounds for enzyme inhibition

MS Smyth, GJ Laidig, RT Borchardt, BA Bunin, CM Crews, JH Musser
US Patent 8,129,346
38 2012

Presentations and Interviews

Interviews 

(Links open in new tab)

 

CDD Spotlights & Webinars

Barry Bunin in conversation with leaders in the scientific community